Legand Biotech Corp. (LEGN) Likely to Receive Approval for Cilta-Cel - Jefferies
Tweet Send to a Friend
Jefferies analyst Biren Amin reiterated a Buy rating and $56.00 price target on Legand Biotech Corp. (NASDAQ: LEGN) on the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
